A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents

Author:

Iriuchishima Hirono1,Saitoh Takayuki2,Handa Hiroshi1,Isoda Atsushi3,Matsumoto Morio3,Sawamura Morio3,Iwasaki Atsushi2,Ushie Chiaki2,Hattori Hikaru2,Sasaki Yoshiko2,Mitsui Takeki1,Yokohama Akihiko4,Tsukamoto Norifumi5,Murakami Hirokazu2,Nojima Yoshihisa1

Affiliation:

1. Department of Medicine and Clinical Science; Gunma University; Maebashi Japan

2. Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Japan

3. Department of Hematology; National Hospital Organization Nishigunma National Hospital; Japan Japan

4. Department of Blood Transfusion; Gunma University Hospital; Maebashi Japan

5. Department of Oncology Center; Gunma University Hospital; Maebashi Japan

Publisher

Wiley

Subject

Hematology,General Medicine

Reference34 articles.

1. Multiple myeloma;Kyle;Blood,2008

2. The survival time of patients with plasmocytic myeloma;Osgood;Cancer Chemother Rep,1960

3. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806);Bergsagel;Cancer Chemother Rep,1962

4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

5. Antitumor activity of thalidomide in refractory multiple myeloma;Singhal;N Engl J Med,1999

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3